Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Valeant Pharmaceuticals International, Inc. (NYSE: VRX).

Full DD Report for VRX

You must become a subscriber to view this report.


Recent News from (NYSE: VRX)

Bausch Health Launches ALTRENO(TM) (tretinoin) Lotion, 0.05% In The United States
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States Canada NewsWire LAVAL, Quebec, Oct. 30, 2018 LAVAL, Quebec , Oct. 30, 2018 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of...
Source: Canada Newswire
Date: October, 30 2018 08:00
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO(TM) (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
ALTRENO Lotion Provides Statistically Significant Greater Efficacy Over Vehicle with a Favorable Safety and Tolerability Profile in Two Pivotal Clinical Trials 1 LAVAL, Quebec , Oct. 11, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, O...
Source: PR Newswire
Date: October, 11 2018 08:00
International Ophthalmology and Optometry Devices Market Booming with New Growth Opportunities
Palm Beach, FL – (July 19, 2018) — The global Ophthalmology Devices market has been anticipated to witness a crucial demand over for the coming near years. According to ResearchMentor.us , the market is estimated to be valued at USD $50 Billion in 2017 and is predicted to extend u...
Source: MarketNewsUpdates.com
Date: July, 19 2018 08:17

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2017-07-1016.4116.6616.9816.3514,591,573
2017-07-0716.6716.2316.7615.9519,318,367
2017-07-0616.8616.6017.3116.5718,722,062
2017-07-0516.9817.1417.3316.5116,280,738
2017-07-0317.3116.9717.4216.849,905,524

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-13179,176433,27841.3536Short
2018-07-1258,289313,55818.5895Cover
2018-07-1166,111205,64532.1481Cover
2018-07-1045,417134,33333.8093Cover
2018-07-09115,565285,05340.5416Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRX.


About Valeant Pharmaceuticals International, Inc. (NYSE: VRX)

Logo for Valeant Pharmaceuticals International, Inc. (NYSE: VRX)

Not available

 

Contact Information

 

 

Current Management

  • Eugene N. Melnyk / CEO
  • Brian H. Crombie / CFO
  • Kenneth C. Cancellara / Secretary

Current Share Structure

  • Market Cap: $7,684,582,554 - 05/31/2018
  • Issue and Outstanding: 349,299,207 - 05/03/2018

 



Daily Technical Chart for (NYSE: VRX)

Daily Technical Chart for (NYSE: VRX)


Stay tuned for daily updates and more on (NYSE: VRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: VRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRX and does not buy, sell, or trade any shares of VRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/